Thomas Zander, Prof. Dr. med Principal Investigator University of Cologne
Kontakt
Thomas Zander, Prof. Dr. med Kontakt: Phone: +49 221 478 Phone (ext.): 87009 E-Mail: thomas.zander@uk-koeln.de» Kontaktdaten anzeigen Hans A Schlößer, PD. Dr. med Kontakt: Phone: +49 221 478 Phone (ext.): 4803 E-Mail: hans.schloesser@uk-koeln.de» Kontaktdaten anzeigen
Studienlocations (2 von 2)
University of Cologne 50937 Cologne (Nordrhein-Westfalen) GermanyRekrutierend» Google-Maps Ansprechpartner: Thomas Zander, Prof. Dr. med. Phone: +49 221 478 Phone (ext.): 87009 E-Mail: thomas.zander@uk-koeln.de
Anja Lohneis, Dr. med. Phone: +49 221 478 Phone (ext.): 30949 E-Mail: anja.lohneis@uk-koeln.de» Ansprechpartner anzeigenBrustzentrum am Klinikum der Universität München Marchioninistraße 15 80337 München DeutschlandRekrutierend» Google-Maps Ansprechpartner: Jens Werner, Prof. Dr. Phone: 089 4400-76573 E-Mail: Jens.werner@med.uni-muenchen.de
Michael von Bergwelt, Prof. Dr. Dr. Phone: 089 4400-72551 E-Mail: sekrmed3@med.uni-muenchen.de» Ansprechpartner anzeigen
1. Evaluation of Safety and efficacy (measured by an increase of pathological complete response rate) (Time Frame - Calculated once at the end of study (24 months after the end of treatment)): The primary objective is to evaluate safety and efficacy (measured by an increase of pathological complete response rate from 20% to 35%) of the fully human monoclonal IgG1 antibody durvalumab targeting the programmed death-ligand 1 (PD-L1) in combination with neoadjuvant radiochemotherapy, followed by surgery for locally advanced esophageal cancer and cancer of the gastric esophageal junction (GEJ).
Secondary outcome:
1. Determination of Best Objective Response (BOR) as defined by RECIST 1.1 and iRECIST criteria after neoadjuvant treatment (Time Frame - Determined once after neoadjuvant treatment (up to 12 weeks after study start)): To determine the Best Objective Response (BOR) as defined by RECIST 1.1 and iRECIST criteria after neoadjuvant treatment
2. Determination of Progression Free Survival (PFS) in durvalumab vs. durvalumab + tremelimumab adjuvant treatment (Time Frame - Until 24 months after the end of treatment): To determine Progression Free Survival (PFS) in durvalumab vs. durvalumab + tremelimumab adjuvant treatment.
PFS is defined as PFS from treatment start to first detection of disease progression.
3. Determination of Disease Free Survival (DFS) in durvalumab vs. durvalumab + tremelimumab adjuvant treatment (Time Frame - Until 24 months after the end of treatment): To determine Disease Free Survival (DFS) in durvalumab vs. durvalumab + tremelimumab adjuvant treatment.
DFS is defined as DFS from time of surgery to first detection of disease progression.
4. Determination of Overall Survival (OS) in durvalumab vs. durvalumab + tremelimumab adjuvant treatment (Time Frame - From the study start until the date of death, assessed up to 240 months): To determine Overall Survival (OS) in durvalumab vs. durvalumab + tremelimumab adjuvant treatment.
OS is defined as OS from treatment start to death.
5. Assessment of the subject's esophageal-cancer-related quality of life using the Functional Assessment of Cancer Therapy-Esophageal (FACT-E) questionnaire (Time Frame - Until 24 months after the end of treatment): To assess the subject's esophageal-cancer-related quality of life using the Functional Assessment of Cancer Therapy-Esophageal (FACT-E) questionnaire.
The questionnaire will be done by interview administration at screening, visit 5 during neoadjuvant treatment, before surgery, after randomization before start of adjuvant treatment and after then every 12 weeks at the time of tumor staging also in the follow-up phase.
Experimental: Durvalumab Treatment arm A will receive durvalumab IV in a dosage of 1500mg every four weeks for 12 months as mono therapy.
Experimental: Durvalumab + Tremelimumab Treatment arm B receives durvalumab in a dosage of 1500mg every 4 weeks (-3/+7 days) for 12 months post-surgery. In addition these patients receive tremelimumab IV in a fixed dose of 75mg for the first four months on day 1; 29; 57; 85 (-3/+7).